TEVA REMINDER: Investors With Losses In Excess of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
TEVA REMINDER: Investors With Losses In Excess of $1,000,000 Are Reminded to Contact the Rosen Law Firm Regarding the Important January 5 Deadline in Class Action Filed by Firm- TEVA

NEW YORK, Dec. 27, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the American Depositary Shares (“ADSs”) of Teva Pharmaceutical Industries Limited (NYSE: TEVA ) between February 10, 2015 and November 3, 2016, both dates inclusive (the “Class Period”) of the important January 5, 2017 lead plaintiff deadline in the class action filed by the firm. The lawsuit seeks recovery of investor losses.  Investors with losses in excess of $1 million are encouraged to contact the firm about the lead plaintiff deadline.

To join the Teva class action, go to http://www.rosenlegal.com/cases-979.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Teva was engaging and/or had engaged in conduct that would result in an antitrust investigation by the U.S. Department of Justice (“DOJ”) and the State of Connecticut Office of the Attorney General; (2) the DOJ investigation and the underlying conduct could cause U.S. prosecutors to file criminal charges against Teva by the end of 2016 for suspected price collusion; (3) in turn, Teva lacked effective internal controls over financial reporting; and (4) as a result, Teva’s public statements were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 5, 2017. If you wish to join the litigation, go to: http://www.rosenlegal.com/cases-979.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com . Attorney Advertising.  Prior results do not guarantee a similar outcome.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm .

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

 

Contact Information:       Laurence Rosen, Esq.       Phillip Kim, Esq.       Kevin Chan, Esq.       The Rosen Law Firm, P.A.       275 Madison Avenue, 34th Floor       New York, NY  10016       Tel: (212) 686-1060       Toll Free: (866) 767-3653       Fax: (212) 202-3827       lrosen@rosenlegal.com       pkim@rosenlegal.com       kchan@rosenlegal.com       www.rosenlegal.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 28

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 34

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 26

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 25

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 19

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 21

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading

Top 5 Most Recently Viewed Articles

Boussard & Gavaudan's NAV Report Highlights for Investors

Updated Category News Views 72

Boussard & Gavaudan Holding Limited: NAV Update Boussard & Gavaudan Holding Limited is pleased to provide a recent update regarding the company's net asset values (NAV) for its Ordinary Shares. Investors are encouraged to stay informed about the performance and returns associated with their investments. Current NAV Estimates The estimated NAV, as of the close of business,...

Continue Reading
Moab Launches Free Shuttle to Enhance Park Access

Updated Category News Views 11

Moab's Shuttle: A New Era for Park Access A breeze of change is sweeping through the dusty trails of Moab, Utah, and this isn't just any switch—it's about making the always-packed Arches National Park a bit less of a traffic nightmare. Imagine this: strolling up to a shuttle, no tickets, no cash needed, and you're off to see epic scenery like The Windows and Delicate...

Continue Reading
Grid Dynamics Shares Upcoming Financial Results Preview

Updated Category News Views 82

Overview of Upcoming Financial Results Announcement Grid Dynamics Holdings, Inc. (Nasdaq: GDYN), recognized as a frontrunner in the digital transformation sector, is preparing to announce its financial results for the fourth quarter and full year of the fiscal year 2024. This much-anticipated event is scheduled for February 20, 2025. Investors and stakeholders can look...

Continue Reading
BioSig Technologies and Streamex Successfully Close $15 Million Offering

Updated Category News Views 154

BioSig Technologies and Streamex Close $15 Million Offering BioSig Technologies, Inc. is excited to share that it has successfully completed a public offering, raising approximately $15 million. The company, now merged with Streamex Exchange Corporation (NASDAQ: BSGM), focuses on gold tokenization infrastructure, positioning itself as a leader in the industry. Details of...

Continue Reading
Navigate Wellbeing Solutions Achieves 2024 Workplace Excellence

Updated Category News Views 64

Navigating Towards Employee Satisfaction Navigate Wellbeing Solutions has proudly secured the Great Place To Work Certification™ for the year 2024. This recognition is a testament to the positive work environment fostered by the organization, as revealed by feedback from employees. An impressive 92% of team members agree it's a great place to work, significantly above...

Continue Reading